Improvement the Anti-migraine Treatment Efficacy by Tailoring the Drug to Individual's Pain Modulation Profile

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

• To delineate brain mechanisms that subserve endogenous analgesic (EA) in the healthy state.

• To identify alterations in mechanisms supporting EA in chronic pain (migraine) and their therapeutic relevance.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Rambam Health Care Campus
• Treatments: Duloxetine Hydrochloride

Criteria

Inclusion Criteria:

• healthy females

• migaine females

• ages 18-50

• for migraineurs: >4 attacks/month

Exclusion Criteria:

• any migraine preventive treatment received during last 3 months or prior treatment with amytriptiline

• other chronic pain conditions

• psychiatric, other neurological diseases, language barrier or cognitive dysfunction

• Patients and controls will be asked to withdraw from any pain-relieving medications for 24 hours before the testing. The tests will be performed interictally atleast 2 days after the last attack.